1. Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev 2008; 88: 1547–65.
2. Ham M, Kaunitz JD. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2008; 24: 665–73.
3. Tulassay Z, Herszenyi L. Gastric mucosal defense and cytoprotection. Best Practice & Research Clinical Gastroenterology 2010; 24: 99–108.
4. Nayeb-Hashemi H, Kaunitz JD. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2009; 25: 537–43.
5. Al-Jiboury H, Kaunitz JD. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2012; 28: 594–601.
6. Palileo C, Kaunitz JD. Gastrointestinal defense mechanisms. Curr Opin Gastroenterol 2011; 27: 543–8.
7. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008; 135:41–60.
8. Robert A, Nezamis JE, Lancaster C et al. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCL, hypertonic NaCl and thermal injury. Gastroenterology 1978; 77: 433–43.
9. Robert A, Nezamis JE, Lancaster C et al. Mild irritants prevent gastric necrosis through adaptive ‘cytoprotection’ mediated prostaglandins. Am J Physiol 1983; 245: G113–21.
10. Wallace JL. Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection. Inflamm Allergy Drug Targets 2006; 5: 133–7.
11. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol 2005; 56 (Suppl. 5): 5–31.
12. Wallace JL, Dicay M, McKnight W, Dudar GK. Platelets accelerate gastric ulcer healing through presentation of vascular endothelial growth factor. Br J Pharmacol 2006; 148: 274–8.
13. Tarnawski A, Stachura J, Ivey KJ et al. Ethanol-induced duodenal lesions in man. Protective effect of prostaglandin. Prostaglandins 1981; 21 (Suppl.): 147–53.
14. Terano A, Ota S, Mach T et al. Prostaglandin protects against taurocholate-induced damage to rat gastric mucosal cellculture. Gastroenterology 1987; 92: 669–77.
15. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49: 443–53.
16. Zanardo RC, Brancaleone V, Distrutti E et al. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 2006; 20: 2118–20.
17. Takeda M, Hayashi Y, Yamato M et al. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. J Physiol Pharmacol 2004; 55: 193–205.
18. Peskar BM. Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing. Inflamm Pharmacol 2005; 13: 15–26.
19. Starodub OT, Demitrack ES, Baumgartner HK, Montrose MH. Disruption of the Cox-1 gene slows repair of microscopic lesions in the mouse gastric epithelium. Am J Physiol Cell Physiol 2008; 294: C223–32.
20. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Annu Rev Physiol 1995; 57: 707–36.
21. Cho CH. Current roles of nitric oxide in gastrointestinal disorders. J Physiol Paris 2001; 95: 253–6.
22. Wallace JL, Miller MJS. Nitric oxide in mucosal defense. A little goes a long-way. Gastroenterology 2000; 119: 512–20.
23. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–12.
24. Furukawa O, Kume E, Sugamoto S et al. Effect of ecabet disodium, a novel locally-acting antiulcer drug, on epithelial restitution following injury by hypertonic NaCl in bullfrog stomach in vitro. Digestion 2000; 62: 116–25.
25. Ichikawa T, Ishihara K, Kusakabe T et al. CGRP modulates mucin synthesis in surface mucus cells of rat gastric oxyntic mucosa. Am J Physiol 2000; 279: G82–9.
26. Li Y, Wang WP, Wang HY et al. Intragastric administration of heparin enhances gastric ulcer healing through a nitric oxide-dependent mechanism in rats. Eur J Pharmacol 2000; 399: 205–14.
27. Ma L, Wallace JL. Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol 2000; 279: G341–6.
28. Chavez-Pina AE, Tapia-Alvarez GR, Reyes-Raminrez A, Navarrete A. Carbenoxolone gastroprotective mechanism: participation of nitric oxide/(c) GMP/K(ATP) pathway in ethanol-induced gastric injury in the rat. Fundam Clin Pharmacol 2011; 25: 717–22.
29. Lanas A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res Ther 2008; 10: 1–6.
30. Mannick EE, Bravo LE, Zarama G et al. Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effects of antibiotics and antioxidants. Cancer Res 1996; 56: 3238–43.
31. Lanas A, Bajador E, Serrano P et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834–9.
32. Lanas A, García-Rodríguez LA, Arroyo MT et al. Investigators of the Asociación Española de Gastroenterología (AEG): Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102: 507–15.
33. Piazuelo E, Fuentes J, Garcfa-Gonzalez MA et al. A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin. Clin Ther 2008; 30: 121–30.
34. Borhade N, Pathan AR, Halder S et al. NO-NSAIDs. Part 3: Nitric Oxide-Releasing Prodrugs of Non-steroidal Anti-inflammatory Drugs. Chem Pharm Bull 2012; 60 (4): 465–81.
35. Reuter BK, Cirino G, Wallace JL: Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 1994; 55: PL1–PL8.
36. Cuzzolin L, Conforti A, Adami A et al. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, NO-naproxen. Pharmacol Res 1995; 31: 61–5.
37. Hawkey CJ, Jones JI, Atherton CT et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003; 52: 1537–42.
38. Lohmander LS, McKeith D, Svensson O et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005; 64: 449-56.
39. Qandil AM. Prodrugs of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), More Than Meets the Eye: A Critical ReviewInt. J Mol Sci 2012; 13: 17244–74.
40. Li Y-H, Li J, Huang Y et al. Gastroprotective effect and mechanism of amtolmetin guacyl in mice. World J Gastroenterol 2004; 10 (24): 3616–20.
41. Bianchi PG, Montrone F, Lazzaroni M et al. Clinical and gastroscopic evaluation of amtolmetin guacylbversus diclofenac in patients with rheumatoid arthritis. Ital J Gastroenterol Hepatol 1999; 31: 378–85.
42. Petazzi I, Corberi G, Bonollo L et al. Clinical study of the therapeutic activity and tolerability of artromed in comparison with piroxicam in rheumatoid arthritic patients. Drugs Exp Clin Res 1990; 16: 31–7.
43. Petazzi I, Corberi G, Bonollo L et al. Evaluation of the time course of the algic-inflammatory symptoms in patients with osteoarthritic afflictions during and after treatment with artromed or diclofenac. Drugs Exp Clin Res 1990; 16: 7–12.
44. Petazzi I, Corberi G, Bonollo L et al. Clinical study of the therapeutic activity and tolerability of artromed in comparison with naproxen in patients with osteoarthritis in different localizations. Drugs Exp Clin Res 1990; 16: 25–30.
45. Bertaccini G, Coruzzi G. Amtolmetin guacyl: a new antiinflammatory drug devoid of gastrolesive properties. Naunyn–Schmiedeberg’s Arch Pharmacol 1998; 358 (Suppl. 1): R366.
46. Riezzo G, Chiloiro M, Montanaro S. Protective effects of amtometin guacyl verus placebo diclofenac and mioprostol in healthy volunteers evaluated as gastric electrical activity in alcohol-induced stomach damage. Dig Dis Sci 2001; 46: 1797–804.
47. Wallace JL. Non-steroidal antiinflammatory drug gastropathy and cytoprotection: pathogenesis and mechanisms reexamined. Scand J Gastroenterol 1992; 27 (Suppl. 192): 3–8.
48. Marcolongo R, Frediani B, Biasi G et al. A Meta-Analysis of the Tolerability of Amtolmetin Guacil, a Novel, Effective Nonsteroidal Anti-Inflammatory Drug, Compared with Established Agents. Clin Drug Invest 1999; 17 (2): 89–96.
49. Jajic´Z, Malaise M, Nekam K et al. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Experim Rheumatol 2005; 23: 809–18.
50. Anon. Amtolmetin guacyl product profile. Adis International 1998.

В.Д.Пасечников

ГБОУ ВПО Ставропольский государственный медицинский университет Минздрава России